The rapid growth in IVT injections has resulted from the introduction of novel drug therapies. In 2004, only 2 agents were specifically approved by the United States Food and Drug Administration for ...
- Geographic atrophy (GA) program introduced with complement Factor I (CFI), a key component of the complement cascade, as a payload and utilizing two intravitreal (IVT) capsids, 7m8 and LSV1 - - IVT ...
Adverum Biotechnologies (ADVM +3.4%) announces the publication of long term pre-clinical safety data for its ADVM-022 intravitreal (IVT) gene therapy in the Translational Vision Science & Technology ...
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Graybug Vision, Inc., a clinical stage pharmaceutical company developing potentially transformative long-acting therapies for ocular diseases, including wet ...
REDWOOD CITY, Calif., April 28, 2021 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM) announced a Suspected Unexpected Serious Adverse Reaction (SUSAR) of hypotony (clinically-relevant ...
- New data highlight that a single intravitreal injection of Ixo-vec can lead to stable and persistent aflibercept expression through three years resulting in fluid control supporting favorable vision ...
EB-105 Targets VEGF-A, -B, PlGF, Ang-2, and IL-6R Improvements in Visual Acuity and Retinal Edema Observed at All Dose Levels No Safety Issues Observed Following a Single Intravitreal (IVT) Injection ...
Multiple subcutaneous doses safe and well-tolerated >69% reduction in anti-VEGF intravitreal (IVT) treatment burden in study eyes >67% reduction in anti-VEGF IVT treatment in fellow eyes of bilateral ...
– Susvimo is the only continuous delivery treatment to provide reliable, long-term vision outcomes in wet AMD, the leading cause of vision loss in people over the age of 60 – – With two refills per ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback